As of today, about 7 million new shares of SYGNIS AG were listed on Frankfurt Stock Exchange's Prime Standard. The shares were predominantly part of a non-cash capital increase following the merger with SYGNIS Biotech (previously X-Pol Biotech), S.L., Madrid, Spain, while a small portion was newly created as part of a cash capital increase. Heuking Kühn Lüer Wojtek legally advised the company on the listing and drafted the required prospectus.
Following the merger between SYGNIS Biotech, specializing in DNA amplification and sequencing, and SYGNIS AG, the company is focusing on developing and marketing SYGNIS Biotech technologies and products in accordance with the newly defined business strategy. In addition to the already marketed SensiPhi® for DNA amplification, SYGNIS Biotech at present develops further products in the field of Next Generation Sequencing.
Responsible for the project
Heuking Kühn Lüer Wojtek:
Dr. Thorsten Kuthe (Capital Markets), Cologne